Table 1 Characteristics of patients with JAK2-mutated ET, mPV and overt PV^a

	ET	Masked PV	Overt PV
N	12	17	20
Age, years, median (range)	65.5 (44–86)	63.0 (34–86)	62.5 (40–88)
Male : Female	3:9	8:9	15:5
Haemoglobin (g/L) ^b
Male	166.0^c	175.5^c	207.0^c
	(160.6–169.6)	(164.1–183.6)	(187.0–240.7)
Female	143.0^c	154.0^c	175.0^c
	(134.4–151.6)	(149.0–161.6)	(169.6–206.8)
Haematocrit (%) ^b
Male	47.0^c	53.0^c	64.0^c
	(45.2–49.7)	(51.4–58.0)	(57.0–73.3)
Female	43.0^c	47.0	55.0^c
	(40.8–47.4)	(44.4–51.2)	(50.8–64.8)
Leukocyte (x10⁹/L)	9.9	11.0	12.6
	(6.3–14.5)	(6.2–19.4)	(9.2–22.2)
Platelets (x10⁹/L)	696^c	663^c	432^c
	(497-1359)	(197-1140)	(210-830)
EPO (IU/mL)^d	6.5	4.0	4.0
	(6.0-6.9)	(2.0–10.0)	(1.0–9.0)
MCV (fL)	87.5	86.1	85.8
	(82.7–91.4)	(73.4–94.4)	(74.7–93.1)
MCV < 80 fL	0/12	5/17	5/20
Ferritin (μg/L)^e	85.0^c	49.0	24.5^c
	(27.2-422.2)	(8.9–233.7)	(10.9–115.7)
Ferritin < 30 μg/L	1/9	6/14	12/20
PB leukocyte JAK2 allele burden (%)^f	18	24	46
	(10.0–39.5)	(8.8–83.6)	(10.3–77.1)
LDH (U/L)	249.0	272.0	308.5
	(141.8–508.8)	(164.8–443.0)	(203.3–484.2)
Urate (mmol/L)	0.31^c	0.39	0.42^c
	(0.24–0.47)	(0.24–0.54)	(0.28–0.59)
Number of BFU-E colonies (%)	725	879	1380
Homozygous mutant	7 (1.0)	110 (12.5)	445 (32.2)
Heterozygous mutant	276 (38.1)	644 (73.3)	475 (34.4)
Wild type	442 (61.0)	125 (14.2)	460 (33.3)

^aUnless specified, data presented are median (5-95th percentile).
^bThe Hb and Hct values reported are the highest recorded at diagnosis or in the preceding 3 months. Patients with a sustained, unexplained Hb increase of ⩾20 g/L exceeding 170 g/L in men or 150 g/L in women were also considered as overt PV.
^cindicates significant difference between the labelled groups with the same symbol, on Dunn’s test for multiple comparisons after a significant Kruskal-Wallis test.
^dEPO levels available for 3 ET, 12 mPV, and 19 overt PV patients.
^eFerritin levels available for 9 ET, 14 mPV and 20 PV patients.
^f1 ET and 1 PV patient had only qualitative JAK2V617F assay.

Search